Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.

Journal of medical virology - 1 Sept 2009

El Makhzangy Hesham, Esmat Gamal, Said Mohamed, Elraziky Maissa, Shouman Soheir, Refai Rasha, Rekacewicz Claire, Gad Rita Raafat, Vignier Nicolas, Abdel-Hamid Mohamed, Zalata Khaled, Bedossa Pierre, Pol Stanislas, Fontanet Arnaud, Mohamed Mostafa K

Abstract excerpt

The safety and efficacy of pegylated interferon (PEG-IFN) alfa-2a and ribavirin were studied among patients treated for genotype 4 chronic hepatitis C. Ninety-five patients with chronic hepatitis C genotype 4 were treated with PEG-IFN alfa-2a (180 microg/week) plus ribavirin (> or =11 mg/kg/day) for 48 weeks. The primary end point was sustained virological response, defined as non-detectable levels of HCV RNA at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Egypt

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Share to Viral Load

Source

Identifiers

PMID: 19626613
DOI: 10.1002/jmv.21570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.PMID 19626613Read ↗

A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response.Semantic proximity Read ↗

Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.Semantic proximity Read ↗

The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian StudySemantic proximity Read ↗

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.Semantic proximity Read ↗

Hepatitis C virus genotype 4 therapy: progress and challenges.Semantic proximity Read ↗

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4.Semantic proximity Read ↗

Hepatis C virus genotype 4.Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin.Semantic proximity Read ↗

Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.Semantic proximity Read ↗

Hepatitis C genotype 4 therapy: increasing options and improving outcomes.Semantic proximity Read ↗

Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.Semantic proximity Read ↗

Hepatitis C genotype 4Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.